Grifols S.A. (GRF)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 10.66 |
|---|---|
| 52-week range | 8.43 – 11.70 |
| Return, 1 month / 3 months | +11.1% / +8.2% |
| Return, 1 year / 3 years | −7.0% / +6.9% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 28.8% |
| Worst drawdown (1 year) | -25.8% |
| Average daily value traded | 12.86M EUR |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Grifols is a Spanish pharmaceutical group based in Barcelona that focuses on medicines made from human blood plasma. It collects plasma at donation centres and processes it into therapies used to treat immune deficiencies, bleeding disorders and other conditions, and it supplies hospitals with intravenous solutions and pharmacy preparation equipment. It also provides diagnostic testing services and instruments. Its customers are mainly hospitals, clinics, blood banks and healthcare providers in Europe, North America and other regions.
The shares are listed on the Madrid Stock Exchange in Spain under the code GRF, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Grifols S.A. (GRF) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 10.66 on 27 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 88 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.0% and over the last three months it rose 8.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.3% | ||
| From 52-week high | -8.7% | ||
| Momentum | 70 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.2% | ||
| 6-month return | 20.0% | ||
| 12-month return, skipping the last month | -16.3% | ||
| Stability (higher is calmer) | 39 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.8% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 12.86M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 6 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.9% |
|---|---|
| 1 month | +11.1% |
| 3 months | +8.2% |
| 6 months | +20.0% |
| 1 year | −7.0% |
| 3 years | +6.9% |
| 5 years | −45.4% |
Signals
| 50-day / 200-day average | 9.87 / 9.66 |
|---|---|
| Golden / death cross (60 days) | Golden, 27 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.24 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Jun 2026 | EUR 0.0824 |
| 11 Aug 2025 | EUR 0.1500 |
| 3 Jun 2021 | EUR 0.3644 |
| 26 Oct 2020 | EUR 0.1616 |
| 2 Dec 2019 | EUR 0.2000 |
| 7 Jun 2019 | EUR 0.1451 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.